risks of glp 1 inhibitors Relative effects glucagon-like peptide-1 (GLP-1) agonists vs Mapping the effectiveness and risks

We have had limited success generating polyclonals and no success generating monoclonals

Increased levels of free fatty acids and pro-inflammatory cytokines synergistically trigger tissue-level desensitization to insulin (53, 5560)

However, if these symptoms are severe, persistent, or worsen over time, they may indicate a more serious issue, potentially evolving into or unmasking underlying gastroparesis

The implant allows for continuous delivery of a GLP-1 receptor agonist, improving cardio-metabolic health and potentially enhancing quality of life while extending it, according to the release

FEBS Lett 592(5):679